Commencement of INX-0125 Phase 1 Clinical Trial Triggers US$1.0 Million Milestone Payment to INEX
Advertisement
Inex Pharmaceuticals Corporation announced that its partner Hana Biosciences has enrolled the first patient in a Phase 1 human clinical trial evaluating the safety, tolerability and preliminary efficacy of INX-0125 (sphingosomal vinorelbine) as a treatment for advanced solid tumors. Commencement of patient dosing for this trial triggers a US$1.0 million milestone payment from Hana to INEX as part of the agreement, in which Hana licensed three products from INEX's Targeted chemotherapy pipeline, including INX-0125.
After INEX pays third-party obligations of approximately US$200,000, the Company will forward the remainder of the Hana milestone payment to former INEX noteholders as provided in an agreement with noteholders. This payment will reduce INEX's future contingent payments to the noteholders from US$24.4 million to US$23.6 million.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
'Smart materials' that make proteins form crystals to boost research into new drugs
Celera and LabCorp Announce Licensing Agreement to Commercialize Breast Cancer Testing Essays